Gene therapy for neurological disorders: progress and prospects

被引：0
作者：
Benjamin E. Deverman
Bernard M. Ravina
Krystof S. Bankiewicz
Steven M. Paul
Dinah W. Y. Sah
机构：
[1] California Institute of Technology,Division of Biology and Biological Engineering
[2] Voyager Therapeutics,Department of Neurological Surgery
[3] University of California–San Francisco,undefined
[4] Present address: Stanley Center for Psychiatric Research at Broad Institute,undefined
[5] Cambridge,undefined
[6] MA,undefined
[7] USA.,undefined
来源：
Nature Reviews Drug Discovery | 2018年 / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The potential of adeno-associated viral (AAV)-mediated gene therapy for neurological disorders is rapidly emerging. Evidence of clinical efficacy and safety, as well as durable transgene expression, has now been reported in several central nervous system disorders. Here, Sah and colleagues discuss key considerations in the design and development of therapeutic AAV vectors, highlighting promising therapeutic targets and recent clinical trials.
引用
收藏
页码：641 / 659
页数：18
相关论文
共 407 条
[1]  
Mendell JR(2017)Single-dose gene-replacement therapy for spinal muscular atrophy N. Engl. J. Med. 377 1713-1722
[2]  
Dominguez E(2011)Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice Hum. Mol. Genet. 20 681-693
[3]  
Foust KD(2010)Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN Nat. Biotechnol. 28 271-274
[4]  
Thomsen GM(2014)Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex J. Neurosci. 34 15587-15600
[5]  
Borel F(2016)Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates Hum. Gene Ther. 27 19-31
[6]  
Foust KD(2013)Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS Mol. Ther. 21 2148-2159
[7]  
McBride JL(2008)Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi Proc. Natl Acad. Sci. USA 105 5868-5873
[8]  
Stanek LM(2014)Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease Hum. Gene Ther. 25 461-474
[9]  
Boudreau RL(2009)Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice Mol. Ther. 17 1053-1063
[10]  
Hocquemiller M(2016)Adeno-associated virus-based gene therapy for CNS diseases Hum. Gene Ther. 27 478-496
12345678910